STC-004 is an oral, highly selective Na V 1.8 inhibitor under development for the treatment of acute and chronic peripheral pain. The phase 1 study, STC-004-CS-001, ...

Like Vertex's Journavx (suzetrigine), cleared by the FDA in February for moderate-to-severe acute pain, STC-004 is an oral inhibitor of the NaV1.8 sodium channel, blocking a pain-signalling ...

STC-004 was well-tolerated at all doses tested, SiteOne previously reported. Eli Lilly stated STC-004 is "Phase II ready" and “may represent a next-generation, non-opioid treatment for patients ...

Called STC-004, the treatment is a a Nav1.8 inhibitor that is ready for Phase 2 testing. Lilly said STC-004 might represent a next-generation, non-opioid treatment for chronic pain.

SiteOne does have NaV1.7 research, but its lead program, STC-004, is designed to selectively block NaV1.8. SiteOne traces its origins to Stanford University, where Mulcahy, ...

The acquisition centers on SiteOne’s STC-004, a Phase 2-ready Nav1.8 inhibitor designed to provide relief for chronic pain sufferers without the risks of addiction associated ...

SiteOne’s STC-004 is an oral small molecule designed to target NaV1.8. In February, SiteOne reported Phase 1 results showing STC-004 was rapidly absorbed with a half-life that supports once ...

Upon the completion of the deal, the company expects to continue the development of STC-004 along with the SiteOne team, paving way for advancement of new non-opioid medicines for pain management.

In February, SiteOne announced positive results from an early-stage study on STC-004, which showed that the drug was safe and well-tolerated at all dose levels while also improving pain tolerance.